* Generation Bio Co GBIO.OQ GBIO.O is expected to show a
rise
in quarterly revenue when it reports results on July 31
(estimated) for the period ending June 30 2024
* The Cambridge Massachusetts-based company is expected to
report
a 122.7% increase in revenue to $1.96 million from $880 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Generation Bio Co is for
a
loss of 28 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Generation
Bio Co
is $7.50, above its last closing price of $3.51.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.40 -0.41 -1.12 Missed -174.4
Dec. 31 2024 -0.44 -0.45 -0.53 Missed -18.2
Jan. 1 0001 -0.50 -0.50 -0.43 Beat 14.9
Jun. 30 2023 -0.50 -0.50 -0.47 Beat 5.4
Mar. -0.45 -0.46 -0.53 Missed -14.2
31 2023
Dec. 31 2022 -0.58 -0.58 -0.55 Beat 5
Sep. 30 2022 -0.66 -0.67 -0.53 Beat 21.1
Jun. 30 2022 -0.63 -0.62 -0.66 Missed -6
This summary was machine generated July 29 at 11:29 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)